Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.39332 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2024. Verfasst von Russell L Rothman und 32 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Acetates, Sulfides, Quinolines, Cyclopropanes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Importance The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain.
Objective
To assess the effectiveness of montelukast compared with placebo in treating outpatients with mild to moderate COVID-19. Design, Setting, and Participants This randomized clinical trial (Accelerating COVID-19 Therapeutic Interventions and Vaccines [ACTIV]–6) was conducted from January 27 through June 23, 2023, during the circulation of Omicron subvariants. Participants aged 30 years or older with confirmed SARS-CoV-2 infection and 2 or more acute COVID-19 symptoms for less than 7 days were included across 104 US sites.
Interventions
Participants were randomized 1:1 to receive montelukast, 10 mg once daily, or matched placebo for 14 days. Main Outcomes and Measures The primary outcome was time to sustained recovery (defined as ≥3 consecutive days without symptoms). Secondary outcomes included time to death; time to hospitalization or death; a composite of health care utilization events (hospitalization, urgent care clinic visit, emergency department visit, or death); COVID-19 clinical progression scale score; and difference in mean time unwell. A modified intention-to-treat approach was used for the analysis.
Results
Among 1250 participants who were randomized and received the study drug or placebo, the median age was 53 years (IQR, 42-62 years), 753 (60.2%) were female, and 704 (56.3%) reported receiving 2 or more doses of a SARS-CoV-2 vaccine. Among 628 participants who received montelukast and 622 who received placebo, differences in time to sustained recovery were not observed (adjusted hazard ratio [AHR], 1.02; 95% credible interval [CrI], 0.92-1.12; P = .63 for efficacy). Unadjusted median time to sustained recovery was 10 days (95% CI, 10-11 days) in both groups. No deaths occurred, and hospitalizations were reported for 2 participants (0.3%) in each group; the composite of health care utilization events was reported for 18 participants (2.9%) in the montelukast group and 18 (2.9%) in the placebo group (AHR, 1.01; 95% CrI, 0.45-1.84; P = .48 for efficacy). Five participants (0.4%) experienced serious adverse events (3 [0.5%] in the montelukast group and 2 [0.3%] in the placebo group). Conclusions and Relevance In this randomized clinical trial of outpatients with mild to moderate COVID-19, treatment with montelukast did not reduce duration of COVID-19 symptoms. These findings do not support the use of montelukast for the treatment of mild to moderate COVID-19. Trial Registration ClinicalTrials.gov Identifier: NCT04885530
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vanderbilt University Medical Center, Nashville, Tennessee.
- School of Data Science, University of Virginia, Charlottesville.
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
- Department of Medicine, University of Minnesota Medical School, Minneapolis.
- Weill Cornell Medicine, New York, New York.
Förderung
- NCATS NIH HHS
Zitieren
APA
Rothman, R. L., Stewart, T. G., Mourad, A., Boulware, D. R., McCarthy, M. W., Thicklin, F., Garcia Del Sol, I. T., Garcia, J. L., Bramante, C. T., Shah, N. S., Singh, U., Williamson, J. C., Rebolledo, P. A., Jagannathan, P., Schwasinger-Schmidt, T., Ginde, A. A., Castro, M., Jayaweera, D., Sulkowski, M., …, & Accelerating COVID-19 Therapeutic Interventions and Vaccines–6 Study Group and Investigators (2024). Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.39332
Vancouver
Rothman RL, Stewart TG, Mourad A, Boulware DR, McCarthy MW, Thicklin F, et al. Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.39332
BibTeX
@article{Rothman2024,
author = {Rothman, Russell L and Stewart, Thomas G and Mourad, Ahmad and Boulware, David R and McCarthy, Matthew W and Thicklin, Florence and Garcia Del Sol, Idania T and Garcia, Jose Luis and Bramante, Carolyn T and Shah, Nirav S and Singh, Upinder and Williamson, John C and Rebolledo, Paulina A and Jagannathan, Prasanna and Schwasinger-Schmidt, Tiffany and Ginde, Adit A and Castro, Mario and Jayaweera, Dushyantha and Sulkowski, Mark and Gentile, Nina and McTigue, Kathleen and Felker, G Michael and DeLong, Allison and Wilder, Rhonda and Collins, Sean and Dunsmore, Sarah E and Adam, Stacey J and Hanna, George J and Shenkman, Elizabeth and Hernandez, Adrian F and Naggie, Susanna and Lindsell, Christopher J and Accelerating COVID-19 Therapeutic Interventions and Vaccines–6 Study Group and Investigators, Accelerating COVID-19 Therapeutic Interventions and Vaccines–6 Study Group and Investigators},
title = {Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.39332}
}
EUVIMED